- Dr Reddy’s Labs Q3 Results: Profit grows 2% YoY to ₹1413 crore; revenue up 16% Mint
- Dr Reddy’s Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth Moneycontrol
- Dr Reddy’s Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16% Business Standard
- Dr Reddy’s Q3 profit up 2% at Rs 1,413 crore; revenue at Rs 8,359 crore The Times of India
- Q3FY25: Dr. Reddy’s to focus on continued CapEx investment, R&D and increasing capacity of existing portfolio The Financial Express
Dr Reddy’s Labs Q3 Results: Profit grows 2% YoY to ₹1413 crore; revenue up 16% MintDr Reddy’s Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth MoneycontrolDr Reddy’s Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16% Business StandardDr Reddy’s Q3 profit up 2% at Rs 1,413 crore; revenue at Rs 8,359 crore The Times of IndiaQ3FY25: Dr. Reddy’s to focus on continued CapEx investment, R&D and increasing capacity of existing portfolio The Financial Express Top stories – Google News